Key result
Midodrine alone, pyridostigmine alone, or their combination similarly improved orthostatic blood pressure drop at 3 months, with mild to moderate adverse events in 11.5% of patients.
Why the study?
Does single or combined therapy with midodrine and pyridostigmine improve orthostatic blood pressure drop in patients with symptomatic neurogenic orthostatic hypotension?
RCT (n=87)
Open-label
randomized
Does single or combined therapy with midodrine and pyridostigmine improve orthostatic blood pressure drop in patients with symptomatic neurogenic orthostatic hypotension?
Answers are grounded in this paper and cite their sources.
Midodrine, pyridostigmine, or their combination are safe and effective for improving orthostatic BP drop in neurogenic OH up to 3 months, with midodrine offering superior symptom relief compared to pyridostigmine.
OBJECTIVE: To evaluate the long-term (for up to 3 months) efficacy and safety of single or combined therapy with midodrine and pyridostigmine for neurogenic orthostatic hypotension (OH). METHODS: This was a randomized, open-label clinical trial. In total, 87 patients with symptomatic neurogenic OH were enrolled and randomized to receive 1 of 3 treatments: midodrine only, pyridostigmine only, or midodrine + pyridostigmine. The patients were followed up at 1 and 3 months after treatment. The primary outcome measures were improvement in orthostatic blood pressure (BP) drop at 3 months. Secondary endpoints were improvement of the orthostatic BP drop at 1 month and amelioration of the questionnaire score evaluating OH-associated symptoms. RESULTS: Orthostatic systolic and diastolic BP drops improved significantly at 3 months after treatment in all treatment groups. Orthostatic symptoms were significantly ameliorated during the 3-month treatment, and the symptom severity was as follows: midodrine only < midodrine + pyridostigmine < pyridostigmine only group. Mild to moderate adverse events were reported by 11.5% of the patients. CONCLUSIONS: Single or combination treatment with midodrine and pyridostigmine was effective and safe in patients with OH for up to 3 months. Midodrine was better than pyridostigmine at improving OH-related symptoms. CLINICALTRIALSGOV IDENTIFIER: NCT02308124. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with neurogenic OH, long-term treatment with midodrine alone, pyridostigmine alone, or both midodrine and pyridostigmine is safe and has similar effects in improving orthostatic BP drop up to 3 months.
No takes yet. Share an insight, caveat, or question.
Byun et al. (2017) conducted an RCT in symptomatic neurogenic orthostatic hypotension (n=87). Midodrine, pyridostigmine, or midodrine + pyridostigmine vs. Active comparators (midodrine vs pyridostigmine vs combination) was evaluated on improvement in orthostatic blood pressure (BP) drop at 3 months. Midodrine alone, pyridostigmine alone, or their combination similarly improved orthostatic blood pressure drop at 3 months, with mild to moderate adverse events in 11.5% of patients.
Synapse has enriched 10 related papers. Consider them for comparative context: